Cancer immunotherapy research has once again topped the R&D charts as one of the hottest fields in biotech. And now MedImmune, the biologics arm of AstraZeneca ($AZN), has teamed up with some prestigious research teams to come up with some revved up combo therapies using a few of their most promising antibodies.
The Cancer Research Institute and the Ludwig Institute will collaborate with MedImmune on new clinical trials of next-gen combo hopefuls, concentrating on pairing the MedImmune antibodies with agents in their own portfolios or outside programs that can be partnered on. MedImmune is contributing its CTLA-4 blocking antibody tremelimumab, an OX40 receptor agonist antibody, and a B7-H1 (or PD-L1) blocking antibody dubbed MEDI4736.
To read the full, original article click on this link: MedImmune partners on trials for a new slate of cancer immunotherapy combos - FierceBiotech
